The efficacy and safety of plerixafor in hematopoietic stem cell mobilization in patients with Non-Hodgkin lymphoma, multiple myeloma, and Hodgkin lymphoma who failed mobilization with granulocyte-colony-stimulating factor alone: A single-center experience
Introduction: Plerixafor is a CXCR4 antagonist which is administered along with granulocyte-colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells in patients with Non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), who failed the mobilization with G-CSF alone. Methodology: This was...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2020-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=4;spage=530;epage=534;aulast=Badarkhe |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850220716595609600 |
|---|---|
| author | Girish Badarkhe Radheshyam Naik |
| author_facet | Girish Badarkhe Radheshyam Naik |
| author_sort | Girish Badarkhe |
| collection | DOAJ |
| description | Introduction: Plerixafor is a CXCR4 antagonist which is administered along with granulocyte-colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells in patients with Non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), who failed the mobilization with G-CSF alone. Methodology: This was a single-center, retrospective study of the efficacy of the plerixafor and G-CSF in 32 patients with NHL (n = 11), MM (n = 11), and Hodgkin lymphoma (HL) (n = 10) who failed mobilization with G-CSF alone. Results: A median number of 1.21 × 106, 1.32 × 106, and 6.73 × 106 CD34 + cells were mobilized in patients with MM, NHL, and HL, respectively. Overall, 31 (96.8%) patients mobilized more than 2 × 106 CD34 + stem cells and 21 (33.75%) patients mobilized more than 5 × 106 CD34 + stem cells. All 32 (100%) patients underwent hematopoietic stem cell transplantation. There were no adverse drug events reported. Conclusion: This retrospective study shows that plerixafor is an effective and safe mobilization agent in patients with NHL, MM, and HL who have failed mobilization with G-CSF alone. |
| format | Article |
| id | doaj-art-7c6b9b3d2c3d458698f545aa6e97a556 |
| institution | OA Journals |
| issn | 0971-5851 0975-2129 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Indian Journal of Medical and Paediatric Oncology |
| spelling | doaj-art-7c6b9b3d2c3d458698f545aa6e97a5562025-08-20T02:06:57ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58510975-21292020-01-0141453053410.4103/ijmpo.ijmpo_154_19The efficacy and safety of plerixafor in hematopoietic stem cell mobilization in patients with Non-Hodgkin lymphoma, multiple myeloma, and Hodgkin lymphoma who failed mobilization with granulocyte-colony-stimulating factor alone: A single-center experienceGirish BadarkheRadheshyam NaikIntroduction: Plerixafor is a CXCR4 antagonist which is administered along with granulocyte-colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells in patients with Non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), who failed the mobilization with G-CSF alone. Methodology: This was a single-center, retrospective study of the efficacy of the plerixafor and G-CSF in 32 patients with NHL (n = 11), MM (n = 11), and Hodgkin lymphoma (HL) (n = 10) who failed mobilization with G-CSF alone. Results: A median number of 1.21 × 106, 1.32 × 106, and 6.73 × 106 CD34 + cells were mobilized in patients with MM, NHL, and HL, respectively. Overall, 31 (96.8%) patients mobilized more than 2 × 106 CD34 + stem cells and 21 (33.75%) patients mobilized more than 5 × 106 CD34 + stem cells. All 32 (100%) patients underwent hematopoietic stem cell transplantation. There were no adverse drug events reported. Conclusion: This retrospective study shows that plerixafor is an effective and safe mobilization agent in patients with NHL, MM, and HL who have failed mobilization with G-CSF alone.http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=4;spage=530;epage=534;aulast=Badarkhehematopoietic stem cell transplantationmultiple myelomanon-hodgkin lymphomaplerixafor |
| spellingShingle | Girish Badarkhe Radheshyam Naik The efficacy and safety of plerixafor in hematopoietic stem cell mobilization in patients with Non-Hodgkin lymphoma, multiple myeloma, and Hodgkin lymphoma who failed mobilization with granulocyte-colony-stimulating factor alone: A single-center experience Indian Journal of Medical and Paediatric Oncology hematopoietic stem cell transplantation multiple myeloma non-hodgkin lymphoma plerixafor |
| title | The efficacy and safety of plerixafor in hematopoietic stem cell mobilization in patients with Non-Hodgkin lymphoma, multiple myeloma, and Hodgkin lymphoma who failed mobilization with granulocyte-colony-stimulating factor alone: A single-center experience |
| title_full | The efficacy and safety of plerixafor in hematopoietic stem cell mobilization in patients with Non-Hodgkin lymphoma, multiple myeloma, and Hodgkin lymphoma who failed mobilization with granulocyte-colony-stimulating factor alone: A single-center experience |
| title_fullStr | The efficacy and safety of plerixafor in hematopoietic stem cell mobilization in patients with Non-Hodgkin lymphoma, multiple myeloma, and Hodgkin lymphoma who failed mobilization with granulocyte-colony-stimulating factor alone: A single-center experience |
| title_full_unstemmed | The efficacy and safety of plerixafor in hematopoietic stem cell mobilization in patients with Non-Hodgkin lymphoma, multiple myeloma, and Hodgkin lymphoma who failed mobilization with granulocyte-colony-stimulating factor alone: A single-center experience |
| title_short | The efficacy and safety of plerixafor in hematopoietic stem cell mobilization in patients with Non-Hodgkin lymphoma, multiple myeloma, and Hodgkin lymphoma who failed mobilization with granulocyte-colony-stimulating factor alone: A single-center experience |
| title_sort | efficacy and safety of plerixafor in hematopoietic stem cell mobilization in patients with non hodgkin lymphoma multiple myeloma and hodgkin lymphoma who failed mobilization with granulocyte colony stimulating factor alone a single center experience |
| topic | hematopoietic stem cell transplantation multiple myeloma non-hodgkin lymphoma plerixafor |
| url | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=4;spage=530;epage=534;aulast=Badarkhe |
| work_keys_str_mv | AT girishbadarkhe theefficacyandsafetyofplerixaforinhematopoieticstemcellmobilizationinpatientswithnonhodgkinlymphomamultiplemyelomaandhodgkinlymphomawhofailedmobilizationwithgranulocytecolonystimulatingfactoraloneasinglecenterexperience AT radheshyamnaik theefficacyandsafetyofplerixaforinhematopoieticstemcellmobilizationinpatientswithnonhodgkinlymphomamultiplemyelomaandhodgkinlymphomawhofailedmobilizationwithgranulocytecolonystimulatingfactoraloneasinglecenterexperience AT girishbadarkhe efficacyandsafetyofplerixaforinhematopoieticstemcellmobilizationinpatientswithnonhodgkinlymphomamultiplemyelomaandhodgkinlymphomawhofailedmobilizationwithgranulocytecolonystimulatingfactoraloneasinglecenterexperience AT radheshyamnaik efficacyandsafetyofplerixaforinhematopoieticstemcellmobilizationinpatientswithnonhodgkinlymphomamultiplemyelomaandhodgkinlymphomawhofailedmobilizationwithgranulocytecolonystimulatingfactoraloneasinglecenterexperience |